ANGO Stock - AngioDynamics, Inc.
Unlock GoAI Insights for ANGO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $292.50M | $303.91M | $338.75M | $316.22M | $291.01M |
| Gross Profit | $157.71M | $154.70M | $174.25M | $165.73M | $156.79M |
| Gross Margin | 53.9% | 50.9% | 51.4% | 52.4% | 53.9% |
| Operating Income | $-39,954,000 | $-192,435,000 | $-51,181,000 | $-28,471,000 | $-35,283,000 |
| Net Income | $-33,993,000 | $-184,349,000 | $-52,442,000 | $-26,547,000 | $-31,548,000 |
| Net Margin | -11.6% | -60.7% | -15.5% | -8.4% | -10.8% |
| EPS | $-0.83 | $-4.59 | $-1.33 | $-0.68 | $-0.82 |
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 16th 2025 | Lake Street | Initiation | Buy | $24 |
| April 5th 2024 | Oppenheimer | Upgrade | Outperform | $12 |
| September 25th 2023 | H.C. Wainwright | Initiation | Buy | $19 |
| April 17th 2023 | Raymond James | Downgrade | Outperform | $13← $14 |
Earnings History & Surprises
ANGOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 31, 2026 | — | — | — | — |
Q1 2026 | Jan 14, 2026 | $-0.10 | — | — | — |
Q4 2025 | Oct 2, 2025 | $-0.14 | $-0.10 | +28.6% | ✓ BEAT |
Q3 2025 | Jul 15, 2025 | $-0.13 | $-0.03 | +76.9% | ✓ BEAT |
Q2 2025 | Apr 2, 2025 | $-0.13 | $0.03 | +123.1% | ✓ BEAT |
Q1 2025 | Jan 8, 2025 | $-0.11 | $-0.04 | +63.6% | ✓ BEAT |
Q4 2024 | Oct 3, 2024 | $-0.15 | $-0.11 | +26.7% | ✓ BEAT |
Q3 2024 | Jul 16, 2024 | $-0.20 | $-0.06 | +70.0% | ✓ BEAT |
Q2 2024 | Apr 4, 2024 | $-0.14 | $-0.16 | -14.3% | ✗ MISS |
Q1 2024 | Jan 5, 2024 | $-0.09 | $-0.05 | +44.4% | ✓ BEAT |
Q4 2023 | Oct 4, 2023 | $-0.14 | $-0.12 | +14.3% | ✓ BEAT |
Q3 2023 | Jul 12, 2023 | $0.02 | $0.02 | -11.1% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.01 | $-0.03 | -300.0% | ✗ MISS |
Q1 2023 | Jan 5, 2023 | $0.00 | $0.01 | +200.3% | ✓ BEAT |
Q4 2022 | Oct 6, 2022 | $-0.02 | $-0.06 | -166.7% | ✗ MISS |
Q3 2022 | Jul 12, 2022 | $0.01 | $0.01 | +33.3% | ✓ BEAT |
Q2 2022 | Apr 7, 2022 | $0.01 | $0.03 | +339.9% | ✓ BEAT |
Q1 2022 | Jan 6, 2022 | $-0.00 | $-0.02 | -481.4% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | $-0.05 | $-0.02 | +60.0% | ✓ BEAT |
Q3 2021 | Jul 13, 2021 | — | $-0.51 | — | — |
Latest News
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $18
📈 PositiveAngioDynamics shares are trading higher after the company raised its FY26 adjusted EPS guidance. Also, the company raised its FY26 sales guidance over estimates.
📈 PositiveAngioDynamics Raises FY2026 Adj EPS Guidance from $(0.35)-$(0.25) to $(0.33)-$(0.23) vs $(0.31) Est; Raises FY2026 Sales Guidance from $305.000M-$310.000M to $308.000M-$313.000M vs $307.200M Est
📈 PositiveAngioDynamics Q1 Adj. EPS $(0.10) Beats $(0.12) Estimate, Sales $75.711M Beat $72.725M Estimate
📈 PositiveFrequently Asked Questions about ANGO
What is ANGO's current stock price?
What is the analyst price target for ANGO?
What sector is AngioDynamics, Inc. in?
What is ANGO's market cap?
Does ANGO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ANGO for comparison